---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011868"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:54:03.406372+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder

## Summary
- $3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.
- 1 million restricted shares issued; no warrants, no discounts, no convertible features.
- Proceeds to fund Telomir-1 IND submission for a rare disease indication.
- Follows prior $1M investment at $7.00/share and complements $5M undrawn line of credit from same group.

## SEC filing metadata
- accession: 0001641172-25-011868
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/0001641172-25-011868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011868
- JSON: https://secwatch.observer/filing/0001641172-25-011868.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.